Application for Listing & Total Voting Rights

Application for Listing

Total Voting Rights

genedrive plc (AIM: GDR), the point of care pharmacogenetic testing company, confirms that in order to support the further drawdown and delivery of its £5M Equity Prepayment facility that was announced on 31 March 2023, application has been made for the Admission to trading on AIM of 4,690,665 new Ordinary Shares of 1.5p each ("New Ordinary Shares"). This application for listing is to satisfy all amounts currently outstanding under the Equity Prepayment facility.

Admission of the New Ordinary Shares ("Admission") is expected to occur on 9 April 2024. Following Admission, the New Ordinary Shares will rank pari passu in all respects with the Company's existing ordinary shares.

Following Admission the Company's issued share capital will consist of 143,141,481 Ordinary Shares of 1.5p each and this figure may be used by shareholders as the denominator for the calculations by which they should determine if they are required to notify their interest in, or change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.